Citations

Clear

949 citation(s) found for "Li, Bryan".

HSR19-107: Nivolumab for Newly Diagnosed Classical Hodgkin Lymphoma: Patient-Reported Outcomes From CheckMate 205 Cohort D
Ramchandren, Radhakrishnan , Ansell, Stephen M. , Armand, Philippe , Engert, Andreas , Taylor, Fiona , Chen, Clara, Bennett, Bryan , Moreno‐Koehler, Alejandro , Roeder, A., Sumbul, Anne, Sacchi, Mariana, Cella, David , Cocks, Kim , Bennett, Bryan

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 26, 2019 | Volume: 17 | Issue: 3.5 | Pages: HSR19-107

10.6004/jnccn.2018.7210 Get It

Background: Patients (pts) with classical Hodgkin lymphoma (cHL) frequently experience reduced health-related quality of life (HRQoL) (Oerlemans et al, Ann Hematol 2011). Nivolumab, a fully human IgG4 anti-programmed death-1 (PD-1) immune checkpoint inhibitor monoclonal antibody, demonstrated efficacy and clinically meaningful improvement in pt-reported outcomes (PROs) in pts with relapsed/refractory cHL in cohorts A, B, and C of CheckMate 205 (NCT02181738) (Armand et al, J Clin Oncol 2018; Engert et al, ASH 2017). Nivolumab monotherapy followed by nivolumab + doxorubicin, vinblastine and dacarbazine (N-AVD) demonstrated an objective response rate of 84% in newly diagnosed cHL (cohort D of CheckMate 205; Ramchandren et al, EHA 2018). We present PROs in CheckMate 205 cohort D. Methods: Pts ≥18 years of age with untreated, advanced-stage cHL, with ECOG performance status (PS) of 0–1 received 4 doses of nivolumab monotherapy (240 mg IV Q2W) followed by N-AVD for 6 cycles (12 doses). Pts then entered the follow-up (FU) period. PROs were an exploratory endpoint, assessed using the EuroQol 5 Dimensions-3 level (EQ-5D-3L) and associated visual analog scale (EQ-VAS) in all treated pts who had both a baseline (monotherapy cycle 1) and post-baseline assessment. EQ-VAS ranges from 0–100, with higher scores indicating better HRQoL. In EQ-5D-3L, pts can report no, some, or extreme problems in each of 5 dimensions (mobility, self-care, activity, pain, and anxiety). Results: 51 pts were treated. At baseline, median age was 37 years, 63% were male, 59% had ECOG PS of 0. 49 pts (96%) completed baseline EQ-VAS. Mean EQ-VAS scores exceeded the mean baseline score at the end of monotherapy, after 2 combination cycles, at the end of therapy, and during follow-up (Table 1). The proportion of pts reporting some or extreme problems in EQ-5D-3L was numerically lower than or similar to baseline after monotherapy for all dimensions, but was numerically higher than baseline (dimensions of mobility and activity) after 2 combination cycles, and remained close to or numerically below baseline during follow-up (dimensions of self-care, activity, pain, and anxiety). Conclusions: Pt-reported HRQoL, as assessed by observed mean EQ-VAS scores, did not deteriorate from baseline during treatment with nivolumab followed by N-AVD. Proportions of pts reporting problems in individual EQ-5D-3L dimensions were generally similar to baseline during treatment and follow-up.
Comparison of Outcomes Based on Graft Type and Tunnel Configuration for Primary Ulnar Collateral Ligament Reconstruction in Professional Baseball Pitchers
Griffith, Timothy B. , Gorroochurn, Prakash , D’Angelo, John , Altchek, David W. , Griffith, Timothy Bryan , Ahmad, Christopher S. , Ciccotti, Michael G. , Dines, Joshua S. , Camp, Christopher L.

Mayo Clinic

The American Journal of Sports Medicine | March 21, 2019 | Volume: 47 | Issue: 5 | Pages: 1103-1110

10.1177/0363546519831705 | PMID 30896975 Get It

Background: Professional baseball pitchers are at high risk for tears of the ulnar collateral ligament (UCL) of the elbow, often requiring surgical reconstruction. Despite acceptable published return-to-play outcomes, multiple techniques and graft types have been described. Purpose: This study compares UCL reconstruction (UCLR) outcomes based on tunnel configuration and graft type. Study Design: Cohort study; Level of evidence, 3. Methods: After approval from our institutional review board and Major League Baseball (MLB), 566 professional baseball pitchers who underwent UCLR between 2010 and 2014 were identified and included. The following patient characteristics were analyzed: age, pitching role (starter vs reliever), level of play (MLB vs Minor League Baseball [MiLB]), and throwing side dominance. Surgical factors analyzed included reconstruction technique, graft type, and concomitant procedures. Primary outcome measures consisted of the ability to return to play at any level (RTP), ability to return to the same level of play (RSL), time to return, subsequent elbow injuries, and need for subsequent or revision elbow surgery. The effects of patient and surgical factors on outcomes were analyzed using multivariate linear and logistic regression modeling. Results: The RTP rate was 79.9%, and the RSL rate was 71.2%. Grafts used to reconstruct the UCL included the palmaris longus autograft (n = 361, 63.7%), the gracilis autograft (n = 135, 23.8%), and other grafts (n = 70, 12.5%). Surgical techniques utilized were the docking technique (n = 171, 30.2%), the modified Jobe technique (n = 290, 51.2%), and other techniques (n = 105, 18.6%). There were no significant differences in the time to RTP or RSL based on reconstruction technique or graft type. RTP rates were similar for the docking versus modified Jobe technique (80.1% vs 82.4%, respectively; P = .537) and for the 2 primary graft types (83.1% for palmaris longus vs 80.7% for gracilis; P = .596). The rate of subsequent elbow surgery was 10.5% for the docking technique versus 14.8% for the modified Jobe technique ( P = .203), and the rate of revision UCLR was 2.9% versus 6.2% for the docking versus modified Jobe technique, respectively ( P = .128). Significant trends toward an increasing use of the palmaris longus autograft ( P = .023) and the docking technique ( P = .006) were observed. MLB pitchers were more likely than MiLB pitchers to RTP ( P < .001) and RSL ( P < .001), but they required a longer time to return (mean difference, 35 days; P = .039) and had a higher likelihood of subsequent elbow (odds ratio [OR], 3.58 [95% CI, 2.06-6.23]; P < .001) and forearm injuries (OR, 5.70 [95% CI, 1.99-16.30]; P = .004) but not subsequent elbow surgery. No specific variables correlated with the rates of subsequent elbow surgery or revision UCLR in the multivariate analysis. The use of concomitant ulnar nerve transposition did not affect outcomes. Conclusion: Surgical outcomes in professional baseball players are not significantly influenced by UCLR technique or graft type. There was a high rate (46.3%) of subsequent throwing elbow injuries. MLB pitchers were more likely to RTP and RSL, but they had a higher frequency of subsequent elbow and forearm injuries than MiLB pitchers. Both the docking technique and the palmaris longus autograft are increasing in popularity among surgeons treating professional baseball players.
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Andrews, Stephanie, Armand, Philippe , Davies, Marianne, Dunnington, David, Frigault, Matthew J. , Hoffner, Brianna, Lunning, Matthew A. , Mohindra, Nisha , Naidoo, Jarushka , Olszanski, Anthony J. , Oluwole, Olalekan O. , Patel, Sandip Pravin , Reddy, Sunil , Ryder, Mabel , Santomasso, Bianca , Shofer, Scott , Sosman, Jeffrey A. , Wahidi, Momen M. , Johnson-Chilla, Alyse, Scavone, Jillian L., Oluwole, Olalekan O , Naidoo, Jarushka , Olszanski, Anthony J , Ryder, Mabel , Bhatia, Shailender , Budde, Lihua E. , Costa, Luciano J. , Ernstoff, Marc S. , Hoimes, Christopher , Lacouture, Mario E. , Locke, Frederick L. , Wang, Yinghong

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 20, 2019 | Volume: 17 | Issue: 3 | Pages: 255-289

10.6004/jnccn.2019.0013 | PMID 30865922 Get It

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neuro-oncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org .
Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
Landa, Iñigo , Korch, Christopher , Smallridge, Robert C., Copland, John A. , Henderson, Ying C. , Lai, Stephen Y. , Clayman, Gary L. , Onoda, Naoyoshi , Tan, Aik Choon , García-Rendueles, María E.R. , Knauf, Jeffrey A. , Haugen, Bryan R. , Schweppe, Rebecca E. , Marlow, Laura A. , Knauf, Jeffrey A , Schweppe, Rebecca E , Tan, Aik Choon , Pozdeyev, Nikita V. , Fagin, James A.

Mayo Clinic

Clinical Cancer Research | February 8, 2019 | Volume: 25 | Issue: 10 | Pages: 3141-3151

10.1158/1078-0432.ccr-18-2953 | PMID 30737244 Get It

Abstract Purpose: Thyroid cancer cell lines are valuable models but have been neglected in pancancer genomic studies. Moreover, their misidentification has been a significant problem. We aim to provide a validated dataset for thyroid cancer researchers. Experimental Design: We performed next-generation sequencing (NGS) and analyzed the transcriptome of 60 authenticated thyroid cell lines and compared our findings with the known genomic defects in human thyroid cancers. Results: Unsupervised transcriptomic analysis showed that 94% of thyroid cell lines clustered distinctly from other lineages. Thyroid cancer cell line mutations recapitulate those found in primary tumors (e.g., BRAF, RAS, or gene fusions). Mutations in the TERT promoter (83%) and TP53 (71%) were highly prevalent. There were frequent alterations in PTEN, PIK3CA, and of members of the SWI/SNF chromatin remodeling complex, mismatch repair, cell-cycle checkpoint, and histone methyl- and acetyltransferase functional groups. Copy number alterations (CNA) were more prevalent in cell lines derived from advanced versus differentiated cancers, as reported in primary tumors, although the precise CNAs were only partially recapitulated. Transcriptomic analysis showed that all cell lines were profoundly dedifferentiated, regardless of their derivation, making them good models for advanced disease. However, they maintained the BRAFV600E versus RAS-dependent consequences on MAPK transcriptional output, which correlated with differential sensitivity to MEK inhibitors. Paired primary tumor-cell line samples showed high concordance of mutations. Complete loss of p53 function in TP53 heterozygous tumors was the most prominent event selected during in vitro immortalization. Conclusions: This cell line resource will help inform future preclinical studies exploring tumor-specific dependencies.
Impact of aggressive combined-modality primary therapy in anaplastic thyroid carcinoma (ATC): An updated single-institution experience.
Prasongsook, Naiyarat , Foote, Robert L. , Molina, Julian R. , Kasperbauer, Jan C., Garces, Yolanda I. , Rubin, Joseph, Richardson, Ronald L., Fatourechi, Vahab , McIver, Bryan, Thompson, Geoffrey B. , Grant, Clive S., Richards, Melanie L., Bible, Keith C. , Daniel, J. , Hay, Ian , Morris, John C., Suman, Vera J.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e17042-e17042

10.1200/jco.2014.32.15_suppl.e17042 Get It

A multicenter international phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
Bible, Keith C. , Molina, Julian R. , Smallridge, Robert C., Maples, William J., Menefee, Michael E., Rubin, Joseph, Karlin, Nina J. , McIver, Bryan, Fatourechi, Vahab , Burton, Jill K., Traynor, Anne M. , Flynn, Patrick J. , Isham, Crescent R., Harris, Pamela Jo , Erlichman, Charles , Suman, Vera J. , Sideras, Kostandinos , Morris, John C., Hay, Ian , Goh, Boon Cher

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 6026-6026

10.1200/jco.2014.32.15_suppl.6026 Get It

Microlobectomy: A Novel Form of Endoscopic Lobectomy
Dunning, Joel , Elsaegh, Mohamed, Gillaspie, Erin A. , Hansen, Henrik Jessen, Helsel, Bryan S., Naase, Hatam, Kornaszewska, Malgorzata, Will, Malcolm , Wigle, Dennis A. , Nardini, Marco , Petersen, René Horsleben , Walker, W. S. G. , Blackmon, Shanda

Mayo Clinic

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | January 3, 2019 | Volume: 12 | Issue: 4 | Pages: 247-253

10.1177/155698451701200403 Get It

American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence‐based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules
Meltzer, Charles , Irish, Jonathan C. , Busaidy, Naifa L. , Dwojak, Sunshine , Haugen, Bryan R. , Harrell, R. Mack, Haymart, Megan R. , McIver, Bryan, Monteiro, Eric, Odell, Michael , Scharpf, Joseph , Shaha, Ashok R. , Shin, Jennifer J. , Thompson, Geoffrey B. , Tuttle, R. Michael , Urken, Mark L. , Wiseman, Sam M. , Meltzer, Charles J , Angelos, Peter , Davies, Louise , Ferris, Robert L. , Mechanick, Jeffrey I. , Morris, John C., Morris, Luc G T , Shonka, David C. , Wong, Richard J. , Randolph, Gregory William

Mayo Clinic

Head & Neck | December 18, 2018 | Volume: 41 | Issue: 4 | Pages: 843-856

10.1002/hed.25526 | PMID 30561068 Get It

AbstractBackgroundCare for patients with thyroid nodules is complex and multidisciplinary, and research demonstrates variation in care. The objective was to develop clinical guidelines and quality metrics to reduce unwarranted variation and improve quality.MethodsMultidisciplinary expert consensus and modified Delphi approach. Source documents were workflow algorithms from Kaiser Permanente Northern California and Cancer Care of Ontario based on the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer.ResultsA consensus‐based, unified preoperative, perioperative, and postoperative workflow was developed for North American use. Twenty‐one panelists achieved consensus on 16 statements about workflow‐embedded process and outcomes metrics addressing safety, access, appropriateness, efficiency, effectiveness, and patient centeredness of care.ConclusionA panel of Canadian and United States experts achieved consensus on workflows and quality metric statements to help reduce unwarranted variation in care, improving overall quality of care for patients diagnosed with thyroid nodules.
New subcutaneous PowerFlow port results in cost and time‐savings in a busy outpatient apheresis clinic
Arnesen, Christine, Gunn, Christina, Boshell, Michael N., Pham, Huy P. , Guillory, Bryan, Adamski, Jill , Williams, Lance A , Pham, Huy P , Marques, Marisa B.

Mayo Clinic

Journal of Clinical Apheresis | December 13, 2018 | Volume: 34 | Issue: 4 | Pages: 482-486

10.1002/jca.21678 | PMID 30548646 Get It

AbstractMany vascular access options, such as subcutaneous ports, are currently on the market for use in both medication infusion and for procedures, such as therapeutic plasma exchange and extracorporeal photopheresis. We compared the cost and time necessary to complete apheresis procedures using either Angiodynamic's Vortex or Bard's PowerFlow subcutaneous ports by reviewing our experience on two patients undergoing long‐term apheresis treatments with at least 10 procedures with each type of port. We analyzed the cost of needles and thrombolytic therapy, staff time, overall procedure length, and the total time the patient was in the apheresis unit. We also compared flow rates and alarm rates between the two ports. In this small pilot study, use of the PowerFlow port resulted in significant cost and time savings, with mixed results for flow rates. Our results need to be confirmed in a larger patient population prior to recommending wide implementation of Bard's PowerFlow port.
A Real‐time Color Doppler Marker for Echocardiographic Guidance of an Acoustically Active Extracorporeal Membrane Oxygenation Cannula
Bëlohlávek, Marek , Vaitkus, Veronica V. , Fatemi, Mostafa , Grabham, Jason, Sandweiss, Bryan M., Katayama, Minako , Kumar, Viksit, Fatemi, Mostafa , Kumar, Viksit

Mayo Clinic

Journal of Ultrasound in Medicine | November 12, 2018 | Volume: 38 | Issue: 7 | Pages: 1875-1885

10.1002/jum.14859 | PMID 30419612 Get It

B‐mode ultrasound imaging guidance of cannulas can be compromised by noise, artifacts, and echogenicity that is not distinctive from that of surrounding anatomy. We have modified a venovenous extracorporeal membrane oxygenation cannula by embedding piezoelectric crystals into each of its 3 blood flow ports. Each vibrating crystal acoustically interacts with a Doppler imaging signal and produces an instantaneous color marker. The aim of this study was to compare identification of the extracorporeal membrane oxygenation cannula ports by B‐mode imaging versus the color Doppler marker. Unlike B‐mode imaging, the color Doppler marker identified the corresponding port even in highly challenging closed‐chest scans in anesthetized pigs. The method could improve guidance accuracy of cannulas by ultrasound scans.